Appreciate the profile www.statnews.com/pharmalot/20... from Ed Silverman & @statnews.com! Amazing progress at Strand Therapeutics advancing field leading genetic medicines. Check my quote on being a nutating mixer if I were a piece of lab equipment ;) #synbio #immunotherapy #cancerresearch

Nature research paper: Humoral determinants of checkpoint immunotherapy go.nature.com/41a8fin

Humoral determinants of checkpoint immunotherapy - Nature

Rapid extracellular antibody profiling reveals a contribution of autoantibodies to the effectiveness of checkpoint immunotherapy for cancer.

go.nature.com

Podcast alert! Enjoyed discussing #ASCO25 #Immunotherapy & #Melanoma data w Dr. Diwakar Davar. Important studies that are advancing the field! @ascocancer.bsky.social dailynews.ascopubs.org/do/podcast-i...

The CheckPoints are ready to party - join us tonight Sunday June 1 at Buddy Guys! Best party of #ASCO25 & all for the great cause of the @sitcancer.bsky.social Forward Fund that supports post-doc & trainee awards. See you tonight!!!

Time for the #AACR25 Annual Reception, featuring the #Checkpoints! Be there tonight 830 PM at McCormick Place West (Level 3) in the Skyline Ballroom (W375). We have a bunch of new tunes & rehearsal was great! @theaacr.bsky.social

Excited to help lead Phase 2/3 frontline metastatic #melanoma TeLuRide-006 study of pembro +/- novel IV TLR7/8 agonist EIK1001. Super interesting pre-clinical & prelim responses in PD1 refractory dz. Trial is open in #Pittsburgh & globally for accrual! clinicaltrials.gov/study/NCT066...

VIP tickets are available now! The CheckPoints will be back in Chicago on June 1 at Buddy Guy’s Legends. Donations will support SITC’s Forward Fund and benefit the next generation of cancer immunotherapy experts. LEARN MORE: www.sitcancer.org/funding/the-... #RockinForACure

Talking IMA203 & SUPRAME trial #iwCART25 in Miami last wknd. Pass the word to #melanoma patients needing novel therapeutics. After ICI, this therapy has possibility for long-term dz control! Trial opening in USA & Europe. 1st pt got IMA203 in Pittsburgh last week! clinicaltrials.gov/study/NCT067...

Extremely excited re: IMA203 - PRAME TCR T cells Ph 1 study published in @natmedicine.bsky.social! This is a transformative Rx in #melanoma for HLA-A201+ & PD1 refractory pts. Compared to TIL, easier to make, less toxic & so far ~2x response rate in heavily pre-Rx. www.nature.com/articles/s41...

A @sitcancer.bsky.social vision statement on accelerating #clinicaltrials to get 100 immunotherapy regulatory approvals in 10 years. Excited to be part of this effort for the paper, for our field but most importantly for the people with #cancer we are working to #cure! jitc.bmj.com/content/13/3...

Tx @theaacr.bsky.social for highlighting our SITC #Checkpoints performance rocking the #AACR25 annual reception in Chicago - Sunday, April 27. The best #cancer science & the best party! Hope everyone will be there! @patrickhwumd.bsky.social @ferranprat.bsky.social www.aacr.org/blog/2025/03...

and we provide some broader #biotech #bioblue context www.sugarconebiotech.com/insights/pd1...

PD1 x VEGF bispecific landscape: examining Hope versus Hype. — SugarCone Biotech

There were waves of interest in this therapeutic space at ASCO in June 2024 and around the JP Morgan healthcare conference in January 2025. Here we take a look at the hope and the hype behind the PD1/...

sugarconebiotech.com

Paul Rennert@pdrworld.bsky.social · last yr.

the ivonescimab clinical data have published in @thelancet.bsky.social www.thelancet.com/journals/lan... and they added some great commentary

Nature research paper: Spatial immune scoring system predicts hepatocellular carcinoma recurrence https://go.nature.com/3Dr0HiQ

Spatial immune scoring system predicts hepatocellular carcinoma recurrence - Nature

A publicly accessible tool—the TIMES score—for predicting the risk of recurrence of hepatocellular carcinoma is revealed, providing mechanistic insights into the prognostic patterns for hepatocellular carcinoma.

go.nature.com

Amazing @sitcancer.bsky.social Spring Scientific on cell therapy in solid tumors! Appreciated op to discuss IMA203. One of the hottest agents in #melanoma & perhaps all of solid tumor oncology! Very excited that the SUPRAME Ph 3 study is now accruing pts! clinicaltrials.gov/study/NCT067...

New Journal for ImmunoTherapy of Cancer ( #JITC ) short report: Phase I dose-escalation and pharmacodynamic study of STING agonist E7766 in advanced solid tumors bit.ly/43bFMuy @jasonlukemd.bsky.social @news.upmc.com @djpinato.bsky.social #OncSky #CanSky #research

Enjoyed discussing LAG3 targeting #melanoma w @drbetofmdphd.bsky.social Major role for relatlimab while fianlimab data look as good/better so far! Field has been waiting long time for RELA-098 but Ph3 studies abound for cemi-fian metastatic, adjuvant and peri-op! www.medscape.org/viewarticle/...

Safer non-viral DNA delivery using lipid nanoparticles loaded with endogenous anti-inflammatory lipids - @pennmedicine.bsky.social go.nature.com/3EkClak

Safer non-viral DNA delivery using lipid nanoparticles loaded with endogenous anti-inflammatory lipids - Nature Biotechnology

Lipid nanoparticles carrying plasmid DNA and an inflammation inhibitor enable longer transgene expression than mRNA nanoparticles.

go.nature.com

🚀 Exciting news! The brand-new #Y2025 #SITC #CompIO Webinar Series is here!!! 🎉 Ten courses focusing on advanced methods and clinical utility for #biomarker #development in IO @sitcancer.bsky.social @roswellpark.bsky.social #NCI 👏 ✨ FREE registration: tinyurl.com/3863jp9t Let's spread the word!🚀

Society for Immunotherapy of Cancer@sitcancer.bsky.social · 2y ago

#SITC is pleased to announce the 2025 SITC-NCI Computational Immuno-oncology Webinar Series! This series will focus specifically on advanced methods and clinical utility for biomarker development in #IO. Learn more about these ten free webinars & register: sitcancer.org/CompIO

Integrating #clinical, #pathological, #radiological, #transcriptomic data boosts prediction of #firstline #immunotherapy outcomes in metastatic #NSCLC 🚀 ✨317 patients, PET/CT, bulk RNAseq, digitized pathology => #Multimodal #AI outperform traditional methods! t.co/MfMNwuZaG9

Excited to speak @sitcancer.bsky.social Spring Scientific: Cellular Therapy for Solid Tumors - March 12–14, San Diego. I'll discuss Development, Clinical Efficacy & Translational Analysis of PRAME Targeting with TCR Transduced T cells via IMA203. Please join us! www.sitcancer.org/education/sp...

Cellular RNAs directly regulate the activity of an antiviral immune signaling complex www.science.org/doi/10.1126/... www.science.org/doi/10.1126/... @science.org @nandangokhale.bsky.social @ramlabuw.bsky.social

Appreciated interview @oncodaily.bsky.social to discuss trends in cancer #immunotherapy, my work, as well as the role of professional societies & mentorship in career development. Focus on what you are passionate about, find great mentors & GRIND! Happy holidays! www.youtube.com/watch?v=HZqA...

Looking forward to moderating this @sitcancer.bsky.social Deep Dive into Co-stim along w Taha Mergoub featuring 3 tremendous talks from rising stars Mohamad Hamieh, Juan Osorio & Roberta Zappasodi covering novel strategies, ICI combos & CART. Please register & join us! sitcancer.org/education/we...

Thanks #ASCO for this recognition as a Fellow! Its an honor contributing to ASCO's important work for patients, providers & the health care community. Onward then in conquering #cancer via research, ed & the highest quality, equitable patient care! See you #ASCO25! society.asco.org/about-asco/a...